CareLit · DOI-Nachweis · Pneumologie
Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF)
DOI 10.1055/s-0036-1572141
Bibliografische Angaben
Nachweis in CareLit
Autor:innenU Costabel, SD Nathan, C Albera, WZ Bradford, EA Fagan, I Glaspole, MK Glassberg, TE King, L Lancaster, DJ Lederer, Z Lin, CA Pereira, JJ Swigris, D Valeyre, PW Noble
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: IPF shows substantial inter- and intra-subject variability in the rates of disease progression, confounding the assessment of therapeutic response in an individual patient. The present analysis used pooled data from three Phase 3 trials to assess the potential benefit of continued treatment with pirfenidone (PFD) in patients who experience a ≥10% decline in forced vital capacity (% FVC) in first 6 months…
Zitieren
Zitierempfehlung
U Costabel, SD Nathan, C Albera, WZ Bradford, EA Fagan, I Glaspole, MK Glassberg, TE King, L Lancaster, DJ Lederer, Z Lin, CA Pereira, JJ Swigris, D Valeyre, PW Noble (2016) Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF). Pneumologie (02). https://doi.org/10.1055/s-0036-1572141
Mit CareLit weiterarbeiten